Trials / Not Yet Recruiting
Not Yet RecruitingNCT07509892
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 198 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy and safety of TQH3906 in treating systemic lupus erythematosus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQH3906 capsule | The TQH3906 capsule is a Tyrosine Kinase 2 (TYK2) inhibitor. |
| DRUG | TQH3906 placebo | Placebo without drug. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-11-01
- Completion
- 2028-03-01
- First posted
- 2026-04-03
- Last updated
- 2026-04-03
Locations
33 sites across 1 country: China
Source: ClinicalTrials.gov record NCT07509892. Inclusion in this directory is not an endorsement.